Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression

Genomically amplified fibroblast growth factor receptor 1 (FGFR1) is an oncogenic driver in defined lung cancer subgroups and predicts sensibility against FGFR1 inhibitors in this patient cohort. The FGFR inhibitor nintedanib has recently been approved for treatment of lung adenocarcinoma and is cur...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Englinger, Bernhard, Lötsch, Daniela, Pirker, Christine, Mohr, Thomas, van Schoonhoven, Sushilla, Boidol, Bernd, Lardeau, Charles-Hugues, Spitzwieser, Melanie, Szabó, Pál, Heffeter, Petra, Lang, Irene, Cichna-Markl, Margit, Grasl-Kraupp, Bettina, Marian, Brigitte, Grusch, Michael, Kubicek, Stefan, Szakács, Gergely, Berger, Walter
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226575/
https://ncbi.nlm.nih.gov/pubmed/27367030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10324
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak